NHS England strikes deal on life-saving gene-therapy drug that can help babies with rare genetic disease move and walk
A life-saving drug that can enable mobility in babies and young children suffering from a rare genetic condition will be available on the NHS, chief executive Sir Simon Stevens yesterday announced.
Zolgensma, which has a reported list price of £1.79 million per dose and is labelled the most expensive drug in the world, will be available to patients at a price that is fair to taxpayers after a landmark confidential deal struck by NHS England.
The one-off gene therapy treats Spinal Muscular Atrophy (SMA), a rare and often fatal genetic disease that causes paralysis, muscle weakness and progressive loss of movement.
Babies born with severe type 1 SMA – the most common form of the condition – have a life expectancy of just two years.
In studies Zolgensma, manufactured by Novartis Gene Therapies, has helped babies to reach milestones such as breathe without a ventilator, sit up on their own and crawl and walk after a single infusion treatment.
NHS England Chief Executive Sir Simon Stevens yesterday said:
“This deal is a life-changer for youngsters with this cruel disease and for their families.
“Spinal Muscular Atrophy is the leading genetic cause of death among babies and young children, which is why NHS England has moved mountains to make this treatment available, while successfully negotiating hard behind the scenes to ensure a price that is fair to taxpayers.
“Although the health service is still under real pressure from covid, and NHS England is also focused on leading the national covid vaccination rollout, today’s agreement is an important reminder that the NHS is looking after millions of other patients too, for whom real medical advances are now possible.”
The deal struck with Novartis Gene Therapies, secures the drug for NHS patients in England at a substantial confidential discount and paves the way for the National Institute for Health and Care Excellence (NICE) to publish draft guidance recommending treatment with Zolgensma.
The terms of the deal mean that some young children that currently fall outside the NICE recommendation criteria will also be eligible to be considered for treatment by a national multidisciplinary clinical team (MDT) made up of the country’s leading experts in the treatment of SMA.
This means as many as 80 babies and young children could potentially benefit from the life-changing gene therapy a year.
The treatment is given as a single intravenous infusion and contains a replica of the missing gene SMN1.
The active ingredient onasemnogene abeparvovec passes into the nerves and restores the gene, which then produces proteins essential for nerve function and controlling muscle movement.
The latest data suggests that Zolgensma can provide rapid and sustained improvement in motor function for young children with type 1 SMA and prolong their lives.
The NHS is ready to fast-track the introduction of the highly complex and innovative gene therapy and will not wait until NICE publish final guidance to get going. This approach is backed by NICE given the importance of administering the one-off treatment as early as possible.
The NHS is currently undertaking a rigorous process to identify centres of excellence to provide the full range services required to administer the treatment safely, with new specialist services treating patients in the coming months. These services require paediatric intensive care and a wide range of other clinical expertise such as neuromuscular, paediatric respiratory medicine, immunology, infectious diseases, hepatology, renal, cardiology and endocrinology.
The approval of the drug marks the second medical treatment now available for youngsters with SMA, after Spinraza became available on the NHS to eligible patients in May 2019. Future treatment possibilities also look promising, with another SMA drug currently being reviewed by NICE.
This is the latest in a series of ‘smart deals’ the NHS has agreed to secure innovative medicines for patients over the past year, while also treating thousands of people with COVID-19 and delivering a rapid COVID-19 vaccines rollout vaccinating 18 million people. Recent agreements have included a first full-access deal in Europe for CAR-T therapy, KTE-X19 for mantle-cell lymphoma, and siponimod as a first oral treatment for secondary progressive multiple sclerosis.
Latest News from
Total NHS COVID vaccines top 96 million, amid concern over new variant29/11/2021 17:15:00
Total vaccinations have hit the 96 million mark as the NHS COVID-19 vaccination programme continues its drive to protect the most vulnerable ahead of Christmas.
More people with diabetes set to benefit from blood sugar monitors as NHS roll-out succeeds29/11/2021 09:15:00
Half of NHS Type 1 diabetes patients in England are now benefiting from the use of “life-changing” flash monitors that allow them to check their glucose levels more easily and regularly, paving the way for more people to benefit.
Record high patient numbers completing NHS treatment for common mental illness26/11/2021 15:43:00
More people got a full course of NHS talking therapy treatment last year than ever before, despite the pressure on services from the pandemic, according to new figures published yesterday.
Third COVID jabs available to book online for people who are severely immunosuppressed26/11/2021 14:51:00
People who are severely immunosuppressed can book their third COVID jab online from today, as the NHS national booking system opens up to more people.
Top up jab bookings to open up for more than one million people22/11/2021 17:20:00
More than one million people will be eligible to book their life-saving jab top-up from tomorrow, as the NHS COVID-19 Vaccination programme continues to boost people’s protection ahead of winter.
NHS deal on spinal muscular atrophy at home treatment22/11/2021 09:15:00
A life-changing drug that can improve mobility in children and adults with a rare genetic condition will be available on the NHS following a new commercial deal, chief executive Amanda Pritchard recently (19 November 2021) announced.
Thousands spared strokes thanks to new NHS drug agreements18/11/2021 09:15:00
More than 20,000 strokes and 5,000 deaths could be averted after NHS England struck new agreements to expand life-saving blood thinning drugs, chief executive Amanda Pritchard recently (16 November 2021) announced.
NHS to open first specialist clinics for severely obese children17/11/2021 09:15:00
Severely obese children and young people will receive intensive support in the coming months thanks to a pilot of 15 new specialist clinics set up by the NHS in England.